Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

Ambarish Pandey; Sushil Kumar Garg; Susan A. Matulevicius; Amil M. Shah; Jalaj Garg; Mark H. Drazner; Alpesh Amin; Jarett D. Berry; Thomas H. Marwick; Steven P. Marso; James A. de Lemos; Dharam J. Kumbhani

doi:10.1161/jaha.115.002137

October 13, 2015Journal of the American Heart AssociationOpen Access

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does mineralocorticoid receptor antagonist (MRA) therapy improve cardiac structure and function in patients with asymptomatic diastolic dysfunction or HFpEF?

Key Points

This research aims to evaluate the effect of mineralocorticoid receptor antagonists (MRAs) on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction (HFPEF).
Conducted a meta-analysis and systematic review of available studies on MRA therapy.
Focused on patients with asymptomatic diastolic dysfunction or HFPEF.
Measured diastolic function and markers of cardiac fibrosis as primary outcomes.
MRA therapy significantly improves diastolic function, as evidenced by improved heart function metrics.
Markers of cardiac fibrosis also show significant improvement post-treatment.
No significant changes observed in left ventricular mass or dimensions.

Structured PICO

Does mineralocorticoid receptor antagonist (MRA) therapy improve cardiac structure and function in patients with asymptomatic diastolic dysfunction or HFpEF?

P

Population

Patients with asymptomatic diastolic dysfunction or heart failure with preserved ejection fraction (HFpEF)

I

Intervention

Mineralocorticoid receptor antagonists (MRA) therapy

O

Outcome

Diastolic function, markers of cardiac fibrosis, and left ventricular (LV) mass or dimensionssurrogate

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

MRA therapy improves surrogate markers of diastolic function and cardiac fibrosis in patients with asymptomatic diastolic dysfunction or HFpEF.

Abstract

MRA therapy in patients with asymptomatic diastolic dysfunction or HFPEF is associated with significant improvement in diastolic function and markers of cardiac fibrosis without a significant change in LV mass or dimensions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pandey et al. (2015) studied this question.

synapsesocial.com/papers/69d56c1075589c71d767cb10 https://doi.org/10.1161/jaha.115.002137

View Full Paper

Ask AI

Bookmark

Share

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading